Henry Schein, Inc. (HSIC) News
Filter HSIC News Items
HSIC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HSIC News Highlights
- HSIC's 30 day story count now stands at 37.
- Over the past 29 days, the trend for HSIC's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
- AMN, BAX and BDX are the most mentioned tickers in articles about HSIC.
Latest HSIC News From Around the Web
Below are the latest news stories about Henry Schein Inc that investors may wish to consider to help them evaluate HSIC as an investment opportunity.
Should Value Investors Buy These Medical Stocks?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
Leith Wheeler Investment Counsel Ltd. Buys Booz Allen Hamilton Holding Corp, Henry Schein Inc, ...Vancouver, A1, based Investment company Leith Wheeler Investment Counsel Ltd. (Current Portfolio) buys Booz Allen Hamilton Holding Corp, Henry Schein Inc, Frontdoor Inc, Global Payments Inc, Accenture PLC, sells Jefferies Financial Group Inc, Hilton Grand Vacations Inc, iShares MSCI EAFE ETF, Charles Schwab Corp, Shopify Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Leith Wheeler Investment Counsel Ltd.. |
Returns On Capital At Henry Schein (NASDAQ:HSIC) Paint A Concerning PictureThere are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a... |
Intuitive Surgical (ISRG) Posts Robust Preliminary Q4 ResultsIntuitive Surgical (ISRG) posts solid fourth-quarter and full-year 2021 results driven primarily by da Vinci procedure volume growth. |
AMN Healthcare (AMN) Reports Solid Preliminary Q4 RevenuesAMN Healthcare's (AMN) solid fourth-quarter results are likely to have been boosted by solid segmental performances. |
DexCom (DXCM) Posts Solid Preliminary Q4 and 2021 RevenuesDexCom (DXCM) posts solid fourth-quarter and full-year 2021 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges. |
BD (BDX) Product Gets FDA Nod, Patient Outcome to Get a BoostRegulatory clearance for BD's (BDX) Kiestra IdentifA system is expected to lead to better patient management via automated sample processing and MALDI target preparation. |
Henry Schein rises on upgrade by Credit SuisseNo summary available. |
Here's Why You Should Retain Baxter (BAX) Stock For NowInvestors continue to be optimistic about Baxter (BAX) due to its strong product portfolio. |
HSIC vs. COO: Which Stock Should Value Investors Buy Now?HSIC vs. COO: Which Stock Is the Better Value Option? |